
ABOUT ZS ASSOCIATES
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products, to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
FEATURED ARTICLES
-
Innovation in cell and gene therapies (CGTs) is leading to rapid growth in the space and transforming standards of care. Learn about the major considerations for developing CGT forecasts.
-
As cell and gene therapies expand, the patient voice will play an increasingly important role in treatment decisions. Learn how pharma can improve the patient experience and more.
-
Experts involved in launching a gene replacement therapy for spinal muscular atrophy share lessons learned during the commercialization journey along with thoughts for other cell and gene therapy manufacturers.
-
Strong results from a phase 2 trial represent a potential inflection point for oncology. Learn about the related implications, barriers to adoption and scale, recommendations for biopharmas, and more.
-
Explore some of the clinical and technical challenges gene therapies face along with a comparison of gene therapy and mAbs, including launched asset success, phase-transition failure rates, and more.
-
Learn about how much hospital-developed CAR-Ts will impact the cell therapy landscape.
-
Learn about the treatment landscape today from surveys collected at CAR-T treatment centers across the U.S. and discussions with payers and treatment centers about CAR-T reimbursement realities.
-
Learn about the numerous opportunities to create differentiation and establish long-term leadership that our research uncovered and how CAR-T manufacturers can refine the processes and experience in clinical trials.
-
We discuss how a deepened understanding of cancer hallmarks and advances in science and engineering have set the stage for emerging therapeutic platforms.
-
We provide a landscape analysis of the industry with a future lens through which we highlight three key insights for C & GT.
-
Learn why strategically embedding a patient-first focus into CGT launch planning today could prove to be valuable investment in a CGT asset’s future.
-
Only a fraction of the population that could benefit from autologous cell therapies are receiving them. Read industry expert perspectives on the evolution of autologous and allogeneic cell therapies.
-
We explore the role gene therapy manufacturers play in addressing the challenge of slow adoption of these therapies to help pave the way for the future.
-
We explore barriers impacting the long-term viability of cell therapy manufacturing including complex delivery logistics and a long end-to-end journey, production capacity and scaling constraints, and manufacturing costs.
-
As the market matures, we expect that the most impactful way to drive volume will not be through breadth alone, it also requires depth in optimizing site potential.
CONTACT INFORMATION
ZS Associates, Inc.
One Boston Place, Floor 28
Boston, MA 02108
UNITED STATES
Phone: (617) 557-5800
SERVICES
WEBINARS
-
While cell and gene therapies have been on the market for years, current distribution has not reached "full scale." Explore challenges to distributing at scale and the potential innovative models to support it.
-
We discuss the implications of the increasing pace of cell and gene therapy development on R&D, technology, and commercialization.
-
Explore how digital solutions can simplify the ordering and managing of cell and gene therapies.